Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Br J Haematol. 2011 Aug;154(4):477-81. doi: 10.1111/j.1365-2141.2011.08781.x. Epub 2011 Jun 28.
Transformed lymphoma (TL) represents a heterogeneous group of lymphomas with an aggressive course and poor prognosis. We assessed the clinical benefit of single-agent lenalidomide based on histological origin, including transformed follicular lymphoma (tFL) and transformed chronic lymphocytic leukaemia/small lymphocytic lymphoma (tCLL/SLL). Our analysis included 33 patients with TL. Patients received lenalidomide at a median dose of 25 mg/d. The overall response rate (ORR) was 46%, with a median response duration of 12·8 months after a median follow-up of 5·6 months. Median progression-free survival was 5·4 months. Among patients with tFL, ORR was 57%, with a median response duration of 12·8 months. None of the patients with tCLL/SLL responded to lenalidomide monotherapy. The most common grade 3/4 adverse events were reversible myelosuppression. Our results suggest that the original lymphoma histology (i.e. FL) in TL patients may potentially be associated with response to salvage lenalidomide monotherapy.
转化淋巴瘤（TL）是一组具有侵袭性病程和预后不良的异质性淋巴瘤。我们评估了基于组织起源的单药来那度胺的临床获益，包括转化滤泡性淋巴瘤（tFL）和转化慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（tCLL/SLL）。我们的分析包括 33 例 TL 患者。患者以 25mg/d 的中位数剂量接受来那度胺治疗。总缓解率（ORR）为 46%，中位缓解持续时间为 12.8 个月，中位随访时间为 5.6 个月。中位无进展生存期为 5.4 个月。在 tFL 患者中，ORR 为 57%，中位缓解持续时间为 12.8 个月。无一例 tCLL/SLL 患者对来那度胺单药治疗有反应。最常见的 3/4 级不良事件是可逆的骨髓抑制。我们的结果表明，TL 患者的原始淋巴瘤组织学（即 FL）可能与挽救性来那度胺单药治疗的反应相关。
